Efficacy and safety of one‐day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft‐versus‐host disease. Issue 8 (28th May 2019)

• Record Type: Journal Article
• Authors: Cid, Joan; Carbassé, Gloria; Suárez‐Lledó, María; Moreno, David F.; Martínez, Carmen; Gutiérrez‐García, Gonzalo; Fernández‐Avilés, Francesc; Rosiñol, Laura; Giavedoni, Priscila; Mascaró, José M.; Agustí, Carles; Marín, Pedro; Rovira, Montserrat; Urbano‐Ispizua, Álvaro; Lozano, Miquel
• Is Part Of: Transfusion. Volume 59:Issue 8(2019)
• Page Start: 2636
• Page End: 2642
• Publication Date: 2019-05-28
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.15384
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract : BACKGROUND: Extracorporeal photopheresis (ECP) has been increasingly used as a second‐line therapy for graft‐versus‐host disease (GVHD) but there is no consensus regarding the best therapeutic schedule. STUDY DESIGN AND METHODS: Our offline ECP schedule for treating patients with GVHD was retrospectively reviewed. Patients with acute GVHD were treated on 2 days per week for the first 2 weeks, followed by 1 day per week for 2 more weeks. After the first month of treatment, patients received treatment 1 day every 2 weeks for a minimum of 16 ECP procedures. Patients with chronic GVHD were treated on 1 day per week for 4 weeks followed by 1 day every 2 weeks for a minimum of 14 ECP procedures. RESULTS: Our series comprises 21 (45%) patients with acute GVHD and 26 (55%) patients with chronic GVHD who received 667 ECP procedures. A median (interquartile range [IQR]) of 1.0 (1.0‐1.12) total blood volume was processed. Patients with acute and chronic GVHD received ECP procedures during a median of 49 (IQR, 14‐103) and 180 (IQR, 111‐274) days, respectively. Mild citrate‐induced symptoms were present in 98 (46%) and 232 (51%) procedures in patients with acute and chronic GVHD, respectively. Overall response rate (ORR) and overall survival (OS) were 57 and 38% (95% confidence interval [CI], 17%‐59%), respectively, for patients with acute GVHD. For patients with chronic GVHD, ORR and OS were 77 and 61% (95% CI, 18%‐87%), respectively. CONCLUSION: Our new offline ECP schedule for treating patients with acute and chronic GVHD was efficacious and safe.